Company

Parabilis Medicines

Parabilis Medicines develops peptide therapeutics using its Helicon™ platform, with a focus on oncology.

About

Parabilis Medicines develops peptide therapeutics using its Helicon™ platform. Its lead candidate, FOG-001 (zolucatetide), is in clinical development for tumors. Founded in 2016, the company is based in Cambridge, US. It raised USD 305 mn in Series F funding, including investment from ARCH Venture Partners and Fidelity Management.

1Funding rounds

19Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in